SONOSCAPE(SZ:300633) Zheng Quan Shi Bao Wang·2025-04-13 07:22Core Viewpoint - The company reported a decline in revenue and net profit for 2024 but anticipates a significant improvement in 2025 due to reduced external policy pressures and controlled internal investment growth [1] Financial Performance - In 2024, the company achieved revenue of 2.014 billion yuan and a net profit of 142 million yuan, both showing a year-on-year decline [1] - The operating cash flow net amount was 307 million yuan [1] - Research and development expenses totaled 473 million yuan, representing a year-on-year increase of 23.08% and accounting for 23.48% of revenue [1] Product Development and Market Position - The company launched high-end ultrasound products, generating revenue of 1.183 billion yuan, and made breakthroughs in the high-end sector with the introduction of the S80 and P80 ultrasound systems [2] - The company’s iEndo intelligent endoscope platform received NMPA registration and is now in the market promotion phase [2] - The company is focusing on integrating artificial intelligence into its product lines, with the fifth-generation AI prenatal ultrasound screening technology completing clinical validation [2] Market Outlook - The medical device industry is expected to improve in 2025, with significant project funding for equipment updates already disclosed, exceeding 80.3 billion yuan [3] - The demand for ultrasound and endoscopic diagnostic services remains strong, and the company is positioned to benefit from the normalization of procurement processes [3] - The company aims to deepen its technological barriers with AI and enhance its global market share and gross margin through the launch of multiple high-end smart products [3]